PT

Advanced Scanners Inc. Announces Company Rebrand & New Name Effective Today: VISIE™ Inc.

Retrieved on: 
Wednesday, November 1, 2023
Biotechnology, Technology, Health, Health Technology, Other Technology, Medical Devices, Research, Software, Surgery, Science, Hardware, 3D, Spine, Neuro, Hope, MD, Doctor of Philosophy, MBA, Multimedia, Surgeon, Marketing, Deep tech, PT, Navy Precision Optical Interferometer, Darkness, Patient, Hospital, Brigham, 3D printing, Cryptocurrency, Dentistry

Advanced Scanners Inc., a 3D computer vision company developing a deep tech optical scanner for orthopedic, neuro, and spine surgery, announces a company rebrand.

Key Points: 
  • Advanced Scanners Inc., a 3D computer vision company developing a deep tech optical scanner for orthopedic, neuro, and spine surgery, announces a company rebrand.
  • Effective immediately, Advanced Scanners will be known as VISIE Inc.
  • View the full release here: https://www.businesswire.com/news/home/20231101737243/en/
    The company makes this announcement after coming out of a 90-day stealth period.
  • In August, the company teased, “From Darkness Comes New Light | 11.01.23,” on its website and LinkedIn, raising eyebrows around the medtech startup industry.

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023
Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Corporation, IOP, AAO, American Academy, NYSE, Retina, Month, American Academy of Ophthalmology, Glaucoma, GKOS, PT, Pharmaceutical industry

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA.
  • Glaukos will be exhibiting onsite at booth #1630.
  • Saturday, November 4, 2023, at 10:00 – 10:30 a.m. PT
    IOP at Month 3 with Travoprost Intraocular Implant vs. IOP at Screening While on Prostaglandin Analog Monotherapy

Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Science, Neoplasm, Patient, FDA, Gemcitabine, Progression-free survival, Biomarker, FOLFIRI, Oregon Health & Science University, PLK1, Knight Cancer Institute, Oregon Health and Science University Center for Women's Health, Clinical uses of mesenchymal stem cells, Pfizer, Cancer, OHSU, University of Pittsburgh Medical Center, CRDF, PT, SAN, ORR, University, SOC, Safety, Dicarboxylic acid, Investment, PR, Pharmaceutical industry, Cryptocurrency

"This has been a transformational quarter for Cardiff Oncology.

Key Points: 
  • "This has been a transformational quarter for Cardiff Oncology.
  • Contingent upon the results of CRDF-004, Cardiff Oncology plans to initiate CRDF-005, a Phase 3, randomized trial with registrational intent.
  • As of September 30, 2023, Cardiff Oncology had approximately $81.4 million in cash, cash equivalents, and short-term investments.
  • Cardiff Oncology will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on November 2, 2023.

American Physical Therapy Association Announces New Editor-In-Chief of PTJ: Physical Therapy & Rehabilitation Journal

Retrieved on: 
Wednesday, November 1, 2023
Duke University School of Medicine, Duke University, Health, MPA, Department of Defense Instruction 1300.28, Doctor of Philosophy, Research, American Physical Therapy Association, Rehabilitation, Growth, Student, Therapy, PT, Bangladesh Technical Education Board, APTA, Oxford University Press, Pharmaceutical industry, Nursing, Orthopedic surgery, PTJ

ALEXANDRIA, Va., Nov. 1, 2023 /PRNewswire/ -- The American Physical Therapy Association announces the appointment of Steven Z. George, PT, PhD, FAPTA, as editor-in-chief of its flagship scientific journal, PTJ: Physical Therapy & Rehabilitation Journal.

Key Points: 
  • ALEXANDRIA, Va., Nov. 1, 2023 /PRNewswire/ -- The American Physical Therapy Association announces the appointment of Steven Z. George, PT, PhD, FAPTA, as editor-in-chief of its flagship scientific journal, PTJ: Physical Therapy & Rehabilitation Journal.
  • George and his collaborators have authored over 320 peer-reviewed publications in leading physical therapy, medical, orthopaedic, rehabilitation, and pain research journals.
  • His research has been funded by the National Institutes of Health, the Department of Defense, and the Academy of Orthopaedic Physical Therapy of the American Physical Therapy Association.
  • The American Physical Therapy Association represents more than 100,000 physical therapists, physical therapist assistants, and physical therapy students nationwide.

Rizing Tide Foundation Announces 2023 Surge Scholarship Recipients and 100% Graduation Rate

Retrieved on: 
Wednesday, November 1, 2023
The Beachcombers, Doctorate, Sport, ATC, DPT, Student, PT, BIPOC, Physical, Nursing, Crest

PHOENIX, Nov. 1, 2023 /PRNewswire/ -- Rizing Tide, a foundation dedicated to creating a more inclusive physical therapy (PT) workforce through its scholarship program focused on supporting racially and ethnically diverse students and residents, proudly unveiled today the 2023 recipients of its annual Surge scholarship program. Three doctors of physical therapy enrolled in residency programs across the United States were selected to receive financial assistance for their residency expenses.

Key Points: 
  • PHOENIX, Nov. 1, 2023 /PRNewswire/ -- Rizing Tide , a foundation dedicated to creating a more inclusive physical therapy (PT) workforce through its scholarship program focused on supporting racially and ethnically diverse students and residents, proudly unveiled today the 2023 recipients of its annual Surge scholarship program .
  • The 2023 Rizing Tide Foundation Surge scholars include:
    "Committed to their professional advancement and to supporting different communities in serious need of board-certified specialty care, the recipients of the 2023 Surge scholarship demonstrate dedication to their craft," said Sharon Hwang , a Rizing Tide Beachcomber and the partner and Chief Operating Officer at MSP Sports Capital.
  • I can't wait to see what the future holds for these three distinguished Surge scholarship recipients."
  • For more information on the Rizing Tide Foundation, including scholarship eligibility requirements, how to apply, and the selection process, visit: www.rizing-tide.com .

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

Retrieved on: 
Tuesday, October 31, 2023
CAR, Therapy, Society for Immunotherapy of Cancer, CARM, Doctor of Philosophy, Entrepreneurship, SITC, Immunotherapy, Doctor of Pharmacy, Messenger, Annual general meeting, LNP, PT, Society, Cancer, Patient, Myelocyte, Pharmaceutical industry, Vaccine, Mitsubishi Carisma, Moderna

PHILADELPHIA, Oct. 31, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that it will present new findings at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting regarding its first-of-its-kind collaboration with Moderna. The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.

Key Points: 
  • The collaboration aims to bring together Carisma's chimeric antigen receptor macrophage (CAR-M) platform with Moderna's mRNA and lipid nanoparticle (LNP) technologies to generate and develop in vivo CAR-M therapeutics.
  • Accepted as a late-breaking presentation, " In vivo CAR-M: Redirecting endogenous myeloid cells with mRNA for cancer immunotherapy ," showcases data that demonstrate Carisma's CAR-M therapy can be directly produced in vivo, or within the body, successfully redirecting endogenous myeloid cells against tumor-associated antigens using mRNA/LNP.
  • "We are pleased to share data about the successful application of our mRNA platform to advance in vivo cell therapy," said Lin Guey, PhD, Chief Scientific Officer of External Research Ventures at Moderna.
  • Details of Carisma data accepted for presentation at the SITC 38th Annual Meeting are as follows:

Argus launches suite of nickel prices with Indonesia's PT IKI

Retrieved on: 
Monday, October 30, 2023
PT, INI, Nickel, Class, ICI, Stainless steel, Argus Media, Argus, MHP, Iron, Platinum, Palladium

In collaboration with PT Indeks Komoditas Indonesia (PT IKI), Argus will publish prices for three grades of Class II nickel and intermediate products as part of the Indonesian Nickel Index (INI) series.

Key Points: 
  • In collaboration with PT Indeks Komoditas Indonesia (PT IKI), Argus will publish prices for three grades of Class II nickel and intermediate products as part of the Indonesian Nickel Index (INI) series.
  • In recent years its prices have disconnected from the Class I nickel (high purity exceeding 99.8%) used to settle exchange traded nickel.
  • All three INI prices will be published as an average of independent assessments for each product by Argus and PT IKI.
  • Argus publishes the widely-referenced Indonesian Coal Index (ICI) benchmarks with PT Coalindo Energy, an affiliate of PT IKI.

Artroniq Spearheads Electric Revolution with Offcial Launch of United E-Motor in Malaysia

Retrieved on: 
Monday, October 30, 2023
Republic, Transport, G20, Partnership, PT, CFO, Development, Bluetooth, Renewable energy, Rare-earth element

Alongside electric motorcycle stunt performances, attendees will experience firsthand the prowess of the TX3000 and TX1800 models.

Key Points: 
  • Alongside electric motorcycle stunt performances, attendees will experience firsthand the prowess of the TX3000 and TX1800 models.
  • The collaboration between seasoned Indonesian brand United E-Motor and Artroniq Bhd is a testament to Artroniq's strategic foresight.
  • I'm confident that our partnership with United E-Motor will unlock unparalleled value for our investors and contribute to a greener future."
  • As at 27 October 2023, the share price of Artroniq is RM0.85, representing a market capitalisation of RM342.0 million.

IBF Net Indonesia Expands Global Footprint with Netversity: A World of Learning Opportunities

Retrieved on: 
Friday, October 27, 2023
Fintech, Islam, Insurance, Economics, Research, IBF, Environment, International Institute for Sustainable Development, Marketing, Ecosystem, PT, ISEF, Investment, Accounting, Communication, Waqf, Climate change, Renewable energy

IBF Net Indonesia is poised to expand its offerings exponentially.

Key Points: 
  • IBF Net Indonesia is poised to expand its offerings exponentially.
  • IBF Net connects with corporate universities run by Indonesian entities for the latter type of courses.
  • Prior to his leadership role with IBF Net Indonesia, Dr Obaidullah served the Jeddah-based Islamic Development Bank Institute as a Lead Research Economist.
  • “This is my dream project working with a team of young and energetic Islamic economists from Indonesia and an international panel of experts,” says Obaidullah.

Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Retrieved on: 
Thursday, October 26, 2023
PLK1, Cancer, PT, SAN, CRDF, Communications satellite, Pharmaceutical industry

SAN DIEGO, Oct. 26, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading.

Key Points: 
  • - Management will hold a conference call on Thursday, November 2 at 4:30 p.m. ET/1:30 p.m. PT -
    SAN DIEGO, Oct. 26, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading.
  • Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on November, 2 2023.
  • Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://cardiffoncology.investorroom.com/events .
  • A replay will be available in the investor relations section on the company's website following the completion of the call.